HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another State Approves Pharmacy Access To Hormonal Contraceptives

US FDA Advisory Panel On OTC Birth Control Nears As Indiana Allows Pharmacist Prescription

Executive Summary

Indiana allows pharmacists, through a standing order from state health agency, to prescribe some hormonal contraceptives in pill or patch form. American College of Obstetricians and Gynecologists among recent supporters of OTC approval in comments to FDA.

You may also be interested in...



For First US OTC Birth Control Application, FDA Extends Time For Advisory Panel Discussion

After postponing planned November advisory committees’ meeting to have time to review more information it requested from sponsor HRA Pharma, FDA sets meeting for 9-10 May. Expanding meeting from one day to a day and a half should allow considering all views and questions about contraceptives.

OTC Birth Control Not Good For Women's Health, Natural Family Planning Group Says

SymptoPro Fertility Education focuses comments to FDA on potential side effects from Opill, suggesting its use could be linked to increased breast cancer risk, depression and ectopic pregnancy. Guttmacher Institute supports approval, saying “adolescents have most to gain.”

US OTC Birth Control NDA Could Debut ‘Additional Conditions for Nonprescription Use’ Labeling

HRA didn't have time to incorporate into its switch NDA instructions stated in proposed ACNU rule published in June, but the firm, which worked with Ibis Reproductive Health on proposal, had time to plumb a draft guidance FDA published in 2018 on novel switches.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153631

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel